Berberrubine

Berberrubine is a protoberberine alkaloid and primary metabolite of berberine, formed via demethylation at the 9-position of the berberine molecule. It interacts with P-glycoprotein efflux transporters and demonstrates enhanced lipid solubility compared to its parent compound, potentially affecting how drugs and nutrients are absorbed and excreted.

Origin & History

Berberrubine is a protoberberine alkaloid and a metabolite of berberine, appearing as a yellow-orange powder. It is derived from plants containing berberine, though specific extraction methods are not detailed.

Historical & Cultural Context

There are no documented traditional or historical medicinal uses for berberrubine. It is recognized as a natural metabolite of berberine rather than a primary compound used historically.

Health Benefits

• Improved lipid solubility and P-glycoprotein affinity compared to berberine, suggesting enhanced bioavailability [5][7]. • Potential to interact with P-glycoprotein, impacting drug transport and metabolism [5]. • Exhibits high efflux ratio, indicating it may influence drug absorption and excretion [5]. • Better P-glycoprotein receptor affinity suggesting potential use in modulating drug resistance [7]. • Higher hydrophobic interactions with P-glycoprotein, which may influence its pharmacokinetic profile [5].

How It Works

Berberrubine exerts its effects primarily through high-affinity interaction with P-glycoprotein (P-gp, encoded by ABCB1), an ATP-dependent efflux transporter expressed in intestinal epithelium, the blood-brain barrier, and hepatocytes. Its enhanced lipid solubility relative to berberine facilitates passive membrane permeation, while its elevated efflux ratio suggests it is actively pumped out of cells via P-gp, influencing net bioavailability and tissue distribution. These pharmacokinetic properties position berberrubine as a modulator of drug transport rather than solely a direct receptor agonist.

Scientific Research

No human clinical trials or meta-analyses specifically on berberrubine were found. Current research is limited to preclinical models and in vitro studies, such as those described in PubMed Central article PMC6318324.

Clinical Summary

Clinical research on berberrubine specifically is extremely limited, with most available data derived from in vitro cell studies and preclinical animal models rather than human trials. Bidirectional transport assays using Caco-2 cell monolayers have demonstrated high efflux ratios for berberrubine, indicating active P-glycoprotein-mediated transport dominates its intestinal handling. No published randomized controlled trials in humans have quantified therapeutic dosages, efficacy endpoints, or safety profiles for isolated berberrubine supplementation. The current evidence base is insufficient to make definitive clinical recommendations, and findings from berberine studies should not be extrapolated directly to berberrubine.

Nutritional Profile

Berberrubine is a pure bioactive alkaloid compound (C19H17NO4, molecular weight ~323.34 g/mol), not a food ingredient, and therefore has no conventional macronutrient or micronutrient profile. It is a naturally occurring metabolite and structural analog of berberine, differing by demethylation at the C-9 position (one fewer methoxy group). As a compound, it is composed entirely of its alkaloid structure with no protein, fat, carbohydrate, fiber, vitamin, or mineral content. Bioactive compound profile: Berberrubine itself is the sole active constituent at 100% concentration in isolated form. It is classified as an isoquinoline alkaloid (protoberberine subclass). Its lipophilicity (logP) is reported to be higher than berberine, enhancing membrane permeability and oral bioavailability. Bioavailability notes: Enhanced lipid solubility compared to berberine improves passive cellular uptake. Exhibits high P-glycoprotein (P-gp) efflux ratio, which may limit net intestinal absorption but also modulates tissue distribution. Metabolically derived in vivo from berberine via demethylation by gut microbiota and hepatic CYP enzymes. Plasma concentrations in pharmacokinetic studies are typically in the nanomolar-to-low micromolar range following oral berberine administration. No dietary reference values (DRIs, RDAs) exist for berberrubine as it is not classified as a nutrient.

Preparation & Dosage

No clinically studied dosage ranges or standardized forms are available due to the absence of human trials. Preclinical studies used a 10 μM concentration in transport assays. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Quercetin, Resveratrol, Green tea extract, Piperine

Safety & Interactions

Berberrubine's strong interaction with P-glycoprotein creates a significant risk of pharmacokinetic drug interactions, as P-gp modulation can alter the absorption and elimination of co-administered drugs including digoxin, cyclosporine, and certain chemotherapeutics. Because P-gp also functions at the blood-brain barrier, berberrubine may influence CNS drug penetration, raising concern when used alongside neurologically active medications. No human safety studies have established a tolerated dose, and its use during pregnancy is contraindicated based on the known uterotonic and potentially embryotoxic properties associated with protoberberine alkaloids as a class. Individuals on polypharmacy regimens, immunosuppressants, or anticoagulants should avoid berberrubine until human pharmacokinetic data are available.